Evidence for or against the efficacy of afterload reducers for management of heart failure in dogs.
Therapeutic decision making is facilitated by knowledge of the short-term and long-term hemodynamic effects of the available vasodilating agents, the nature and prevalence of their adverse side effects, and their abilities to ameliorate the signs of heart disease, to improve exercise capacity, and to prolong patient survival. This article is intended to provide the reader with a comprehensive list of the available afterload-reducing agents, to review the relevant studies of these drugs in humans and dogs with heart failure, and to provide guidelines for their use in commonly encountered clinical situations.